07:27 AM EDT, 07/28/2025 (MT Newswires) -- Zymeworks ( ZYME ) said Monday the US Food and Drug Administration has cleared its investigational new drug application for the conduct of a phase 1 trial of ZW251 in hepatocellular carcinoma, the most common form of liver cancer.

The company said it plans to start clinical trials in 2025.

Shares of the company were up more than 10% in recent premarket activity Monday.